The encapsulated, anti‐CD133 antibody‐coated nanoparticle treatment more selectively killed TICs and reduced tumor viability (Figure S10C, Supporting Information), indicating that nanoparticles with anti‐CD133 antibody coating were more selective for killing TICs. This evidence concerns the gene PROM1 and neoplasm.